The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers. (December 2016) - Blake, J.; Kolakowski, G.R.; Tuch, B.; Ebata, K.; Brandhuber, B.; Winski, S.; Bouhana, K.; Nanda, N.; Wu, W.I.; Parker, A.; Hamor, R.; Larsen, P.D.; et al.